Chronic infection with Chlamydia pneumoniae in asthma: a type-2 low infection related phenotype.
Asthma
Chlamydia pneumoniae
Macrolides
Neutrophils
Phenotypes
Sputum
Journal
Respiratory research
ISSN: 1465-993X
Titre abrégé: Respir Res
Pays: England
ID NLM: 101090633
Informations de publication
Date de publication:
26 Feb 2021
26 Feb 2021
Historique:
received:
18
09
2020
accepted:
24
01
2021
entrez:
27
2
2021
pubmed:
28
2
2021
medline:
6
11
2021
Statut:
epublish
Résumé
Chlamydia pneumoniae and Mycoplasma pneumoniae have been implicated in the pathogenesis of asthma and are responsible for chronic inflammation when host immune system fails to eradicate the bacteria. We performed a prospective study on 410 patients who underwent a visit at the asthma clinic of CHU of Liege between June 2016 and June 2018 with serology testing for C. pneumoniae and M. pneumoniae. 65% of our asthmatic population had serum IgA and/or IgG towards C. pneumoniae, while only 12.6% had IgM and/or IgG against M. pneumoniae. Compared to seronegative asthmatics, asthmatics with IgA+ and IgG+ against C. pneumoniae were more often male and older with a higher proportion of patients with smoking history. They received higher doses of inhaled corticosteroids (ICS) and displayed lower FEV Positive Chlamydia serologic test is more common than positive Mycoplasma serology. Asthmatics with IgA and IgG against C. pneumoniae have more severe disease with increased airway obstruction, higher doses of ICS, more signs of air trapping and less type-2 inflammation.
Sections du résumé
BACKGROUND
BACKGROUND
Chlamydia pneumoniae and Mycoplasma pneumoniae have been implicated in the pathogenesis of asthma and are responsible for chronic inflammation when host immune system fails to eradicate the bacteria.
METHOD
METHODS
We performed a prospective study on 410 patients who underwent a visit at the asthma clinic of CHU of Liege between June 2016 and June 2018 with serology testing for C. pneumoniae and M. pneumoniae.
RESULTS
RESULTS
65% of our asthmatic population had serum IgA and/or IgG towards C. pneumoniae, while only 12.6% had IgM and/or IgG against M. pneumoniae. Compared to seronegative asthmatics, asthmatics with IgA+ and IgG+ against C. pneumoniae were more often male and older with a higher proportion of patients with smoking history. They received higher doses of inhaled corticosteroids (ICS) and displayed lower FEV
CONCLUSION
CONCLUSIONS
Positive Chlamydia serologic test is more common than positive Mycoplasma serology. Asthmatics with IgA and IgG against C. pneumoniae have more severe disease with increased airway obstruction, higher doses of ICS, more signs of air trapping and less type-2 inflammation.
Identifiants
pubmed: 33637072
doi: 10.1186/s12931-021-01635-w
pii: 10.1186/s12931-021-01635-w
pmc: PMC7913423
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
72Références
J Infect Chemother. 2009 Apr;15(2):99-103
pubmed: 19396519
PLoS Clin Trials. 2006 Jun;1(2):e11
pubmed: 16871333
Chest. 1999 May;115(5):1265-70
pubmed: 10334138
JAMA. 1991 Jul 10;266(2):225-30
pubmed: 2056624
J Allergy Clin Immunol. 2010 Oct;126(4):747-53
pubmed: 20920764
J Allergy Clin Immunol. 2016 Apr;137(4):1017-1023.e6
pubmed: 26586037
Ann Med. 1998 Feb;30(1):27-37
pubmed: 9556087
Lancet. 2017 Aug 12;390(10095):659-668
pubmed: 28687413
Ann Allergy. 1993 Jan;70(1):23-5
pubmed: 8424592
Clin Diagn Lab Immunol. 2000 Sep;7(5):734-8
pubmed: 10973446
J Pediatr. 1986 May;108(5 Pt 1):659-64
pubmed: 3701509
J Clin Invest. 1994 Jul;94(1):97-104
pubmed: 7518836
Am J Respir Cell Mol Biol. 1998 Nov;19(5):721-7
pubmed: 9806736
PLoS One. 2012;7(4):e35945
pubmed: 22545149
J Allergy Clin Immunol. 2001 Mar;107(3):449-54
pubmed: 11240944
Infect Immun. 1996 Apr;64(4):1488-90
pubmed: 8606126
Respir Res. 2021 Jan 13;22(1):15
pubmed: 33441106
J Allergy Clin Immunol. 2004 Jan;113(1):59-65
pubmed: 14713908
J Allergy Clin Immunol. 2015 Jan;135(1):25-30
pubmed: 25567040
Thorax. 2013 Apr;68(4):322-9
pubmed: 23291349
Chest. 2002 Jun;121(6):1782-8
pubmed: 12065339
J Fam Pract. 1995 Aug;41(2):153-7
pubmed: 7636455
Infect Immun. 2003 Mar;71(3):1520-6
pubmed: 12595471
Int J Gen Med. 2010 Dec 20;4:1-4
pubmed: 21403784
Infect Immun. 2002 Jul;70(7):3649-55
pubmed: 12065506
Allergy Asthma Immunol Res. 2012 Mar;4(2):92-7
pubmed: 22379604
Thorax. 1998 Apr;53(4):254-9
pubmed: 9741366
J Allergy Clin Immunol. 2017 Feb;139(2):519-532
pubmed: 27448447
Eur Respir J. 2000 Feb;15(2):254-9
pubmed: 10706488
Heliyon. 2020 Feb 29;6(2):e03512
pubmed: 32140608
Eur Respir J. 1999 Oct;14(4):902-7
pubmed: 10573240
Thorax. 1998 Dec;53(12):1095
pubmed: 10195087
J Allergy Clin Immunol. 2005 Nov;116(5):1123-8
pubmed: 16275386
Pediatr Infect Dis J. 2010 Dec;29(12):1093-8
pubmed: 21155094
Lancet Respir Med. 2016 Mar;4(3):e8
pubmed: 26973164
Ann Allergy Asthma Immunol. 2008 Dec;101(6):614-8
pubmed: 19119705
J Infect Dis. 1990 Apr;161(4):618-25
pubmed: 2181028
Respir Res. 2017 May 19;18(1):98
pubmed: 28526018
Am J Respir Crit Care Med. 2001 Aug 15;164(4):536-41
pubmed: 11520711
PLoS One. 2013 Dec 20;8(12):e83453
pubmed: 24376704
Epidemiol Infect. 1996 Dec;117(3):513-7
pubmed: 8972677
Am J Respir Crit Care Med. 2001 Apr;163(5):1097-100
pubmed: 11316642
Eur Respir J. 2002 Oct;20(4):834-40
pubmed: 12412672
Am J Respir Crit Care Med. 2005 Nov 1;172(9):1078-89
pubmed: 15961690
PLoS One. 2011;6(12):e27912
pubmed: 22205932